# EDGAR Filing Document

**Accession Number:** 0001735438
**File Stem:** 0001193125-26-000949
**Filing Date:** 2026-1
**Character Count:** 13719
**Document Hash:** 616c5f37228e77b4067249efe61e39a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-000949.hdr.sgml**: 20260102

**ACCESSION NUMBER**: 0001193125-26-000949

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260102

**DATE AS OF CHANGE**: 20260102

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MeiraGTx Holdings plc
- **CENTRAL INDEX KEY:** 0001735438
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981448305
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90529
- **FILM NUMBER:** 26502645

**BUSINESS ADDRESS:**
- **STREET 1:** 655 THIRD AVENUE
- **STREET 2:** SUITE 1115
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 646-860-7985

**MAIL ADDRESS:**
- **STREET 1:** 655 THIRD AVENUE
- **STREET 2:** SUITE 1115
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERCEPTIVE ADVISORS LLC
- **CENTRAL INDEX KEY:** 0001224962

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003
- **BUSINESS PHONE:** 646-205-5300

**MAIL ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**MeiraGTx Holdings plc**

*(Name of Issuer)*

**Ordinary Shares, nominal value $0.00003881 per share**

*(Title of Class of Securities)*

**G59665102**

*(CUSIP Number)*

**Alexander Rakitin**<br>Perceptive Advisors LLC, 51 Astor Place<br>10th Floor<br>New York NY 10003<br>(646) 205-5345

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/31/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G59665102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Advisors LLC** | Name of reporting person<br>**Perceptive Advisors LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10441562.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10441562.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10441562.00** | Aggregate amount beneficially owned by each reporting person<br>**10441562.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.9%** | Percent of class represented by amount in Row (11)<br>**12.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **G59665102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Joseph Edelman** | Name of reporting person<br>**Joseph Edelman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10441562.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10441562.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10441562.00** | Aggregate amount beneficially owned by each reporting person<br>**10441562.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.9%** | Percent of class represented by amount in Row (11)<br>**12.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **G59665102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Life Sciences Master Fund, Ltd.** | Name of reporting person<br>**Perceptive Life Sciences Master Fund, Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10441562.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10441562.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10441562.00** | Aggregate amount beneficially owned by each reporting person<br>**10441562.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.9%** | Percent of class represented by amount in Row (11)<br>**12.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, nominal value $0.00003881 per share

**(b) Name of Issuer:**
MeiraGTx Holdings plc

**(c) Address of Issuer's Principal Executive Offices:**
450 East 29th Street, 14th Floor, New York, NY, 10016

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5(a)-(c) of the Schedule 13D are amended and supplemented as follows:

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on 80,490,889 outstanding Ordinary Shares as of October 28, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and give effect to the exercise of 115,459 vested stock options and 95,000 shares issuable upon the settlement of deferred share units that the Advisor has rights to pursuant to a management fee offset, as described below.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Ellen Hukkelhoven, the Head of Investment Research of the Advisor, holds (i) stock options exercisable for a total of 115,459 Ordinary Shares, all of which are currently exercisable, and (ii) 140,000 deferred share units, of which 95,000 have vested or will vest within 60 days.

**(c)**
On December 31, 2025, the Master Fund sold 2,300,000 Ordinary Shares to the Issuer at a price per share of $7.91 pursuant to the Share Purchase Agreement (as defined in Item 6 below). Item 6 of the Schedule 13D is incorporated by reference. Except as described herein, none of the Reporting Persons has effected any transaction in the Ordinary Shares in the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is amended and supplemented as follows:

On December 31, 2025, the Master Fund entered into a share purchase agreement (the "Share Purchase Agreement") with the Issuer, pursuant to which the Issuer agreed to purchase 2,300,000 Ordinary Shares from the Master Fund at a price of $7.91 per share (which was the volume-weighted average price (VWAP) per share on the Nasdaq Global Select Market on December 31, 2025), for an aggregate purchase price of $18,193,000 (the "Share Repurchase").  The transaction contemplated by the Share Purchase Agreement is expected to close on January 5, 2026.

Pursuant to the terms of the Share Purchase Agreement, the Master Fund agreed that it and its affiliates will not, without the Issuer's prior written consent, sell, transfer or dispose of any Ordinary Shares (the "Lock-Up Securities"), or any securities convertible into or exercisable or exchangeable for the Ordinary Shares, or otherwise make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of the Lock-Up Securities, until twelve (12) months from the closing date of the Share Repurchase, provided that the foregoing restriction does not prohibit  (a) the Master Fund from transferring any Lock-Up Securities to the Issuer or any transfers contemplated by the Securities Purchase Agreement, including the Share Repurchase; or (b) the disposition of Lock-Up Securities pursuant to (i) any merger, consolidation or similar transaction to which the Issuer is a constituent corporation, (ii) a bona fide tender offer or exchange offer made to all of the holders of capital stock by a person or entity other than the Master Fund (or any of its affiliates or any person or entity acting on behalf of or as part of a group or in concert with the Master Fund or any of its affiliates), (iii) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the Master Fund, or to any investment fund or other entity controlling, controlled by, managing or managed by the Master Fund or affiliates of the Master Fund, or (iv) as part of a distribution, transfer or disposition by the Master Fund to the Master Fund's stockholders, current or former partners (general or limited), members, beneficiaries or other equity holders, or to the estates of any such stockholders, partners, beneficiaries or other equity holders.

The foregoing description of the Share Purchase Agreement is qualified in its entirety by reference to the full text of the agreement, a copy of which is included as Exhibit 6 hereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Advisors LLC

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Member

**Date:** 01/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Joseph Edelman

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman

**Date:** 01/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Life Sciences Master Fund, Ltd.

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Member

**Date:** 01/02/2026